Saenger Amy K, Jaffe Allan S
Department of Laboratory Medicine and Pathology, Mayo Clinic, Gonda Building-5th floor, 200 First Street SW, Rochester, MN 55905, USA.
Med Clin North Am. 2007 Jul;91(4):657-81; xi. doi: 10.1016/j.mcna.2007.04.001.
The advent of inexpensive, highly accurate, and predictive markers of myocardial injury, inflammation, and hemodynamic stability has revolutionized the evaluation and treatment of patients who have acute coronary syndromes (ACSs). These blood biomarkers require small sample volumes, can be run expeditiously, and provide important information concerning the diagnosis, risk stratification, and treatment of these patients. To understand the use of these markers, one must have some knowledge about what elevations in these markers imply, how they have to be collected and measured to provide reliable information, when to suspect analytic confounds, and what the key values are that impart the diagnostic, prognostic, and therapeutic information. This article discusses these issues, emphasizing what clinicians must know for optimal test use, and then addresses the practical use of these markers in patients who have ACS.
廉价、高度准确且具有预测性的心肌损伤、炎症及血流动力学稳定性标志物的出现，彻底改变了急性冠脉综合征（ACS）患者的评估与治疗方式。这些血液生物标志物所需样本量小，检测迅速，能提供有关此类患者诊断、风险分层及治疗的重要信息。要理解这些标志物的用途，必须了解这些标志物升高意味着什么，如何采集和检测才能提供可靠信息，何时怀疑分析结果存在混淆，以及赋予诊断、预后和治疗信息的关键值是什么。本文将讨论这些问题，着重阐述临床医生为实现最佳检测应用必须了解的内容，然后探讨这些标志物在ACS患者中的实际应用。
